BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 823087)

  • 1. [Clinical treatment of peripheral arterial occlusive diseases].
    Schulte B
    Fortschr Med; 1976 Sep; 94(27):1500-4. PubMed ID: 823087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Conservative treatment of peripheral arterial occlusive diseases].
    Hoffmann J
    Fortschr Med; 1978 Sep; 96(34):1735-8. PubMed ID: 101431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of chronic arterial occlusive disease. Studies with an orally administered drug under ambulatory conditions].
    Wampola H
    Fortschr Med; 1977 May; 95(18):1240,1242-5. PubMed ID: 405291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Observations during ambulatory therapy of functional and organic circulatory disorders with Defluina].
    Brüning G
    Med Welt; 1975 Sep; 26(38):1737-41. PubMed ID: 810634
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
    Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
    Maksimović ZV
    Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl].
    Kling H
    Fortschr Med; 1979 May; 97(19):926-8. PubMed ID: 109382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of peripheral vascular diseases with dihydroergocristine].
    Moracchini PV; Alfano G; Melandri F
    Minerva Cardioangiol; 1978 Apr; 26(4):277-90. PubMed ID: 97601
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease.
    Milio G; Cospite V; Cospite M
    Minerva Cardioangiol; 2003 Jun; 51(3):311-6. PubMed ID: 12867883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride].
    Seboldt H
    Fortschr Med; 1980 Feb; 98(7):257-60. PubMed ID: 6767648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug therapy of arterial diseases. A study with Trental 400].
    Tannenberg G
    Fortschr Med; 1980 Dec; 98(45):1795-8. PubMed ID: 7461576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical trial of Trental 100 in patients with peripheral arterial occlusive diseases (author's transl)].
    von Westphalen JG
    MMW Munch Med Wochenschr; 1977 Jul; 119(26):901-4. PubMed ID: 408616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
    Chopra HK; Chopra KL; Aggarwal KK; Parashar SK
    J Med; 1988; 19(2):89-107. PubMed ID: 3049876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vasoactive drugs in peripheral arterial perfusion disorders. Problems, principles and results of the determination of therapeutic efficacy].
    Heidrich H
    Dtsch Med Wochenschr; 1985 Aug; 110(31-32):1219-24. PubMed ID: 3926447
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypervolumetric hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study.
    Koscielny J; Latza R; Pruss A; Kiesewetter H; Jung F; Meier C; Schimetta W
    Clin Hemorheol Microcirc; 2000; 22(1):53-65. PubMed ID: 10711822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
    Allegra C; Antignani PL; Schachter I; Koverech A; Messano M; Virmani A
    Ann Vasc Surg; 2008; 22(4):552-8. PubMed ID: 18502605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of cutaneous necrosis risk in peripheral arterial diseases].
    D'Eri A; Martini R; Cordova RM; Trevisan G; Andreozzi GM
    Minerva Cardioangiol; 2002 Jun; 50(3):239-44. PubMed ID: 12107403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasodilating effects of celiprolol in patients with peripheral obliterative arterial disease.
    Diehm C
    J Int Med Res; 1988; 16 Suppl 1():34A-38A. PubMed ID: 2975611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic occlusive arterial disease with pentoxifylline: changes in clinical and haemodynamic parameters.
    Schweiger H; Ortmeier CJ
    Pharmatherapeutica; 1989; 5(5):298-304. PubMed ID: 2526340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
    Riccioni C; Sarcinella R; Palermo G; Izzo A; Liguori M; Koverech A; Messano M; Virmani A
    Int Angiol; 2008 Jun; 27(3):253-9. PubMed ID: 18506129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.